Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).

Respiratory research·2026

Same author

Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy.

Swiss medical weekly·2026

Same author

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026

Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026

Same author

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

The New England journal of medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Interstitial Lung Disease Associated with Systemic Sclerosis.

Valentine Mismetti¹, Salim Si-Mohamed^2,3, Vincent Cottin^1,4

¹Department of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, ERN-LUNG, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France.

Seminars in Respiratory and Critical Care Medicine

|May 7, 2024

Summary

This summary is machine-generated.

Systemic sclerosis (SSc) is a rare autoimmune disease. This review covers the latest evidence for diagnosing and managing SSc-associated interstitial lung disease (SSc-ILD), a major cause of mortality.

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Related Experiment Videos

Last Updated: Jun 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Published on: April 30, 2019

Area of Science:

Rheumatology
Pulmonology
Immunology

Background:

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy, fibrosis, and immune-mediated inflammation.
Interstitial lung disease (ILD) prevalence in SSc ranges from 25-95% and is a leading cause of mortality.
Pulmonary manifestations significantly impact SSc morbidity and mortality.

Purpose of the Study:

To provide an overview of the latest evidence for diagnosing and managing SSc-ILD.
To summarize current therapeutic options and emerging expert consensus for SSc-ILD management.
To guide clinicians with evidence-based practices for SSc-ILD patients.

Main Methods:

Review of recent randomized controlled trials and expert consensus.
Analysis of diagnostic approaches for SSc-ILD.
Evaluation of therapeutic interventions including mycophenolate, rituximab, tocilizumab, and nintedanib.

Main Results:

SSc-ILD is a critical determinant of outcomes in systemic sclerosis.
Several medications show efficacy in treating SSc-ILD.
Ongoing research aims to refine management strategies and guidelines.

Conclusions:

Optimizing therapeutic management for SSc-ILD is crucial.
Evidence-based clinical practice guidelines are emerging for SSc-ILD.
Continued research is necessary to address remaining uncertainties in SSc-ILD care.